Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

115.42 -1.72 (-1.47%)
Delayed Quote Updated: 12:37 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
3 Profitable Stocks for Long-Term Investors
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financia... 
Via StockStory
News headline image
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Incyte
Via Business Wire
News headline image
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out ↗
Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody... 
Via MarketBeat
INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup ↗
Via Chartmill
News headline image
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
From Genesis Molecular AI and Incyte
Via Business Wire
Incyte (NASDAQ:INCY) Beats Q1 Estimates and Unveils Robust Pipeline Catalysts ↗
Via Chartmill
Incyte Corp. (NASDAQ:INCY) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
From Incyte and Edison Scientific
Via Business Wire
News headline image
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build ↗
Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business,... 
Via MarketBeat
News headline image
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
From Incyte
Via Business Wire
News headline image
2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
Via StockStory
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
News headline image
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions
Incyte’s first quarter results were shaped by strong demand across its commercial portfolio, with growth supported by both new and existing products in hemat... 
Via StockStory
Topics Earnings
News headline image
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
INCY Q1 Deep Dive: Pipeline Advances Offset Cautious Full-Year Guidance
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 20.9% year on year to $1.27 bi... 
Via StockStory
News headline image
Incyte (INCY) Q1 2026 Earnings Call Transcript ↗
Incyte (INCY) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Incyte (INCY) Q2 2025 Earnings Transcript ↗
Incyte (INCY) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 20.9% year on... 
Via StockStory
News headline image
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
From Incyte
Via Business Wire
News headline image
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
From Incyte
Via Business Wire
News headline image
Incyte Earnings: What To Look For From INCY
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for. Incyte beat analy... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte (INCY) Q4 2024 Earnings Transcript ↗
Incyte (INCY) Q4 2024 Earnings Transcript 
Via The Motley Fool
News headline image
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Incyte
Via Business Wire
News headline image
INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup ↗
Incyte Corp (INCY) shows strong earnings growth and a positive technical setup, suggesting a potential breakout for momentum investors. 
Via Chartmill
News headline image
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
News headline image
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
From Adagene Inc.
Via GlobeNewswire
News headline image
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The bio... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.